- Details
- Description
-
Packaging Size60C/bottle
-
Strength200mg&250mg
-
CompositonCrizotinib
-
TreatmentALK+ non-small cell lung cancer (NSCLC) ,ROS1 + non-small cell lung cancer (NSCLC) ,ALK+ inflammatory myofibroblastic tumors (IMT) ,
-
FormCapsule
-
BrandKayzoni
-
Quantity Unit200mg*60C/Bottle & 250mg*60C/Bottle
-
ManufacturerTongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）
Crizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.
Non-Small Cell Lung Cancer
Indicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive
250 mg PO BID
Continue until disease progression or unacceptable toxicity
Inflammatory Myofibroblastic tumors
Indicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive
250 mg PO BID
Continue until disease progression or unacceptable toxicity
Dosage Modifications
- First dose reduction: 200 mg PO BID
- Second dose reduction: 250 mg PO qDay
- Unable to tolerate 250 mg PO qDay: Permanently discontinue
